Skip to main content

Table 2 Ganetespib-related grade 3 adverse events

From: A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer

N Ganetespib-related grade 3 adverse events Outcome
1a Grade 3 blurred vision/grade 3 dry eyes (in same patient)a Blurred vision: dose held for 1 week until ≤ grade 1 and paclitaxel dose reduced to 65 mg/m2/ Dry eyes: no action taken: resolved in 1 week
1 Grade 3 pruritus While attributed to ganetespib, symptoms resolved after paclitaxel was held
1 Grade 3 phosphorus, decreased No action taken; resolved in 1 day
1 Grade 3 ALT, increased Ganetespib and paclitaxel dose held for 1 week; resolved in 1 week
  1. ALT alanine aminotransferase
  2. aOne patient had blurred vision and dry eyes which were felt to be attributable to paclitaxel based on her having similar symptoms when treated with paclitaxel in the past. She was followed by an ophthalmologist for this toxicity which resolved with the discontinuation of paclitaxel